Silo Pharma Partners with Zylo Therapeutics

Sustained Transdermal delivery method to become essential for Alzheimers and Parkinsons patients with Dysphagia.

FREMONT, CA: Silo Pharma, a developmental stage biopharmaceutical firm focused on the use of psychedelics as a therapeutic, enters into a Joint Venture with Zylo Therapeutics.  This Joint Venture will utilize Zylos innovative sustained-release topical delivery system developed at Albert Einstein College of Medicine, leveraging Silo Pharma’s expertise in the use of psychedelics. The joint venture will explore the clinical development of ketamine using ZTIs Z-pod technology and offers for Silo Pharma to get an exclusive option for the clinical effect of psilocybin using ZTIs Z-pod technology as well.

Eric Weisblum, CEO of Silo Pharma, stated This Joint Venture is part of Silo Pharma’s vision of bringing therapeutics to patients in need.  The ability to offer Ketamine or Psilocybin in a time-released manner will enable us to explore both the safety and efficacy of the therapeutics while hopefully diminishing the hallucinogenic impacts of psychedelics.  We believe that Zylo’s patented technology will help to reach potential patients that suffer from Dysphagia, like both Alzheimers and Parkinsons patients.

Zylo Therapeutics is exceptionally excited to be entering into this partnership with Silo Pharma, a company with broad-ranging expertise in psychedelics. Ketamine is a versatile drug that continues to show promise with novel therapeutic indications. The company is looking forward to leveraging proprietary topical delivery technology to build a low-dose, sustained-release ketamine formulation that is safe and convenient for patients.

Silo Pharma. is a developmental stage biopharmaceutical organization focused on merging traditional therapeutics with psychedelic research for people suffering from depression, PTSD, Parkinsons, and other rare neurological diseases. Silos mission is to identify assets to license and fund the investigation, which the companies believe will be transformative to the well-being of patients and the health care sector.